Imugene Limited (AU:IMU) has released an update.
Imugene Limited announced the successful passing of all resolutions at its Annual General Meeting, despite facing a ‘first strike’ due to over 25% of votes opposing the 2024 Remuneration Report. The company remains committed to advancing its innovative immuno-oncology therapies and is well-positioned to achieve significant milestones in the global cancer treatment market.
For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.
